scispace - formally typeset
Open AccessJournal ArticleDOI

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

TLDR
Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
About
This article is published in Atherosclerosis.The article was published on 2019-09-02 and is currently open access. It has received 2972 citations till now. The article focuses on the topics: Lipid modification & Very low-density lipoprotein.

read more

Citations
More filters
Journal ArticleDOI

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential.

TL;DR: Inclisiran offers an advantage against medication non-compliance, which is one of the main causes for not achieving LDL-C goals with standard therapy, and has a relatively safe profile with adverse effects occurring in similar frequency as with placebo.
Journal ArticleDOI

Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis.

TL;DR: In this paper, a systematic review of published evidence regarding statin treatment and COVID-19 related mortality was performed, which showed that statin therapy was associated with an about 35% decrease in the adjusted risk of mortality in hospitalized COVID19 patients.
Journal ArticleDOI

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta‐Analysis of Randomized Controlled Trials

TL;DR: A systematic review and meta‐analysis on efficacy and safety of BA compared with standard treatment in patients with hypercholesterolemia found that BA is associated with a significant reduction in low‐density lipoprotein cholesterol, total cholesterol, non–high‐density cholesterol, apolipoprotein B, and hs‐CRP compared withstandard treatment.
Journal ArticleDOI

What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery

TL;DR: Post hoc analyses of clinical trials with proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors have shown that these drugs exert clinical benefits by lowering Lp(a), independent of their potent reduction of low-density lipoprotein cholesterol (LDL-C).
Journal ArticleDOI

Effects of Cardiovascular Risk Factor Variability on Health Outcomes

TL;DR: Recent evidence regarding the role of variability in metabolic parameters, which can be measured by continuous glucose monitoring systems or self-monitoring of blood glucose levels, is reviewed and the clinical implications of these findings are discussed.
References
More filters
Journal ArticleDOI

Atherosclerosis — An Inflammatory Disease

TL;DR: Atherosclerosis is an inflammatory disease as discussed by the authors, and it is a major cause of death in the United States, Europe, and much of Asia, despite changes in lifestyle and use of new pharmacologic approaches to lower plasma cholesterol concentrations.
Journal ArticleDOI

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Giuseppe Mancia, +89 more
TL;DR: In this article, a randomized controlled trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people was presented. But the authors did not discuss the effect of the combination therapy in patients living with systolic hypertension.
Journal Article

Atherosclerosis is an Inflammatory Disease

TL;DR: Despite changes in lifestyle and the use of new pharmacologic approaches to lower plasma cholesterol concentrations, cardiovascular disease continues to be the principal cause of death in the United States, Europe, and much of Asia.

Standards of Medical Care in Diabetes

TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Related Papers (5)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, +120 more